Ebenezer A. Kio

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio et al. · Annals of Oncology · 2021 · 349 citations

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA

Yoko Otake, Sridharan Soundararajan, Tapas K. Sengupta et al. · Blood · 2006 · 233 citations · Full text

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse et al. · Cancer · 2020 · 158 citations · Full text

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub et al. · Clinical Cancer Research · 2017 · 155 citations · Full text